share_log

BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress; Co. Reports 'Trial did not meet the co-primary efficacy endpoints; no new safet

BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress; Co. Reports 'Trial did not meet the co-primary efficacy endpoints; no new safet

BEY基因提供扎努布魯替尼治療新冠肺炎相關肺窘迫患者的第二階段臨牀試驗的最新情況；Co.Reports公司的試驗沒有達到共同的主要療效終點；沒有新的SAFET
Benzinga Real-time News ·  2021/04/08 19:08

BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress; Co. Reports 'Trial did not meet the co-primary efficacy endpoints; no new safety signals identified'

BEY基因提供了扎努布魯替尼治療新冠肺炎相關肺窘迫患者的第二階段臨牀試驗的最新情況；公司報道説，試驗沒有達到共同的主要療效終點；沒有發現新的安全信號。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論